J
J. Craig Forrest
Federal Grant PI
High Impact
Professor
faculty
27 h-index
66 pubs
2,922 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
J. Craig Forrest's research program investigates the pathogenesis of gammaherpesviruses, focusing on viral replication, latency, and the intricate interactions between these viruses and host immune cells, particularly B lymphocytes. His work utilizes murine models to understand the molecular mechanisms underlying viral persistence and disease development. Forrest has received significant federal funding from the National Institutes of Health (NIH) to support these investigations. Awards include funding from the National Cancer Institute for studies on gammaherpesvirus-driven genomic instability in B cells and the role of periodontal bacteria in oral KSHV pathogenesis, as well as funding from the National Institute of Allergy and Infectious Diseases for research into KSHV LANA functions in viral pathogenesis and immune evasion, and the role of lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses.
His recent publications demonstrate a dual focus. Several papers address the serological response to SARS-CoV-2, including pediatric seroprevalence in Arkansas and temporal variations by race and ethnicity, reflecting contributions to broader public health research on the COVID-19 pandemic. Concurrently, his laboratory continues to publish on gammaherpesvirus biology, with recent work exploring the role of STAT3 signaling in B cells during murine gammaherpesvirus 68 infection and the mechanisms by which replication-deficient vaccines protect against disease and latency. Forrest's scholarship metrics include an h-index of 27, with 65 total publications and over 2,900 citations.
Metrics
- h-index: 27
- Publications: 66
- Citations: 2,922
Selected Publications
-
The amplitude of gammaherpesvirus lytic replication dictates adaptive immune activation: Potential implications for KSHV LANA in immune evasion (2026)
-
Intrinsic p53 activation restricts gammaherpesvirus driven germinal center B cell expansion during latency establishment (2025)
-
Vaccination with a Replication-Dead Murine Gammaherpesvirus Lacking Viral Pathogenesis Genes Inhibits WT Virus Infection (2024)
-
Vaccination with a Replication-Dead Murine Gammaherpesvirus Lacking Viral Pathogenesis Genes Inhibits WT Virus Infection (2024)
-
Molecular Mechanisms of KSHV Latency Establishment and Maintenance (2024)
-
A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment (2024)
-
Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models (2024)
-
Intrinsic p53 Activation Restricts Gammaherpesvirus-Driven Germinal Center B Cell Expansion during Latency Establishment (2023)
-
Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice (2023)
-
Uracil-DNA glycosylase of murine gammaherpesvirus 68 binds cognate viral replication factors independently of its catalytic residues (2023)
-
A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University (2023)
-
Uracil-DNA Glycosylase of Murine Gammaherpesvirus 68 Binds Cognate Viral Replication Factors Independently of its Catalytic Residues (2023)
-
B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model (2023)
-
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization (2022)
-
Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency <i>In Vivo</i> (2022)
Federal Grants 5 $2,050,700 total
NIH/National Cancer Institute
Contact PI
Apr 2026 - Mar 2031
Defining the pathogenesis of gammaherpesvirus and Plasmodium coinfections
NIH/National Institute of Allergy and Infectious Diseases
Contact PI
Jun 2025 - May 2027
Lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses
NIH/National Institute of Allergy and Infectious Diseases
Contact PI
Jul 2024 - May 2029
Defining KSHV LANA functions in viral pathogenesis and immune evasion
NIH/National Cancer Institute
Co-PI
Mar 2019 - Apr 2025
NIH/National Cancer Institute
Contact PI
Apr 2014 - Feb 2027
Defining mechanisms of gammaherpesvirus-driven genomic instability in B cells
Collaboration Network
Top Collaborators
Shana M. Owens
University of Arkansas for Medical Sciences
16 shared publications
In database
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency <i>In Vivo</i>
Showing 5 of 16 shared publications
Karl W. Boehme
10 shared publications
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection
Showing 5 of 10 shared publications
Laurie T. Krug
National Cancer Institute (US)
9 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Uracil-DNA glycosylase of murine gammaherpesvirus 68 binds cognate viral replication factors independently of its catalytic residues
- Uracil-DNA Glycosylase of Murine Gammaherpesvirus 68 Binds Cognate Viral Replication Factors Independently of its Catalytic Residues
Showing 5 of 9 shared publications
Joshua L. Kennedy
8 shared publications
In database
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection
Showing 5 of 8 shared publications
Laura P. James
University of Arkansas for Medical Sciences (US)
7 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Modifying laboratory testing via home brew during the COVID-19 pandemic
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
Showing 5 of 7 shared publications
Darby G. Oldenburg
Gundersen Health System (US)
7 shared publications
- Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency <i>In Vivo</i>
- Intrinsic p53 activation restricts gammaherpesvirus driven germinal center B cell expansion during latency establishment
- Uracil-DNA glycosylase of murine gammaherpesvirus 68 binds cognate viral replication factors independently of its catalytic residues
- Lytic Replication and Reactivation from B Cells Is Not Required for Maintaining Gammaherpesvirus Latency <i>in vivo</i>
- Uracil-DNA Glycosylase of Murine Gammaherpesvirus 68 Binds Cognate Viral Replication Factors Independently of its Catalytic Residues
Showing 5 of 7 shared publications
Namvar Zohoori
Arkansas Department of Health (US)
6 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
Showing 5 of 6 shared publications
Benjamin C. Amick
Winthrop Rockefeller Foundation (US)
5 shared publications
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University
Jessica Snowden
Arkansas Children's Hospital
5 shared publications
In database
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University
Catherine Kirkpatrick
Arkansas Children's Hospital
5 shared publications
In database
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Zeel Modi
Arkansas Children's Hospital (US)
5 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Katherine Caid
Arkansas Children's Hospital (US)
5 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Wendy N. Nembhard
University of Arkansas for Medical Sciences
5 shared publications
In database
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- A longitudinal study of SARS-CoV-2 antibody seroprevalence and mitigation behaviors among college students at an Arkansas University
Chad H. Hogan
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Varvara Kirillov
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Similar Researchers
Based on overlapping research topics
Shana M. Owens
University of Arkansas for Medical Sciences
Viral Infections and Vectors
Herpesvirus Infections and Treatments
Immune Cell Function and Interaction
Steven R. Post
University of Arkansas for Medical Sciences
Viral Infections and Vectors
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Jiao Song
University of Arkansas for Medical Sciences
Viral Infections and Vectors
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Lu Dai
University of Arkansas for Medical Sciences
Viral Infections and Vectors
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Lindsey Barrett
University of Arkansas for Medical Sciences
Viral Infections and Vectors
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Catherine Kirkpatrick
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
T-cell and B-cell Immunology
Cancer-related molecular mechanisms research